The United Nations General Assembly is set to hold a special session on the world drug problem in Manhattan this week, and those in the cannabis space are watching closely to see whether the meeting could bring any changes in global drug rules.
For decades, international drug policies have focused on the prohibition and criminalization of drug use, an approach that has lead to violence, corruption and mass incarceration. Writing for the Weed Blog, Phillip Smith points out that drug related violence has left at least 100,000 dead in Mexico alone over the past decade. Tens of thousands more have”disappeared.”
Governments, specifically those of Latin American countries, are calling for more evidence-based drug policies, and as Open Society Foundations explains, UNGASS 2016 may be the first time that an international debate on drugs does more than simply reinforce the status quo.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

Slow to change

But while the conversation may be open, many are skeptical that the meeting will produce real change. Currently, there are three treaties that effectively enforce global drug prohibition and the UN’s 1998 vision for a “drug free world.” They are:


  • The 1972 Protocol amending the Single Convention on Narcotic Drugs (Single Convention of 1961)
  • The 1971 Convention on Psychotropic Substances (CPS)
  • The 1988 Convention against Illicit Traffic in Narcotic and Psychotropic Substances

None of these treaties are up for discussion in this week’s meeting. As OpenCanada.org notes, in the outcome document that’s being recommended for adoption at the UNGASS “[t]he preamble ‘reaffirms’ and ‘underlines’ the three drug control conventions.”
Still, countries such as the United States have already made moves to legalize cannabis within their own borders, arguing that their changes in policy are still within the bounds of the treaty. Meanwhile, Justin Trudeau has said that Canada will look to legalize cannabis at the federal level, treaties or not.
“This is significant, as any possibilities for reforming the international drug control treaties can only come to bear once countries decide that the treaties are no longer fit for purpose – and that starts with acknowledging that cannabis legalization isn’t permitted,” states OpenCanada.

What does it mean for investors?

Speaking to the Investing News Network, Alan Brochstein of 420 Investor stated that a change to the treaties could mean big changes for the cannabis space.
Why? “Because you could have a global change in how nations view cannabis,” he said. Brochstein that the treaties mentioned above are outdated, and that many nations moving towards evidence-based policies don’t believe in them anymore.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

To be sure, Mexican Senator Laura Angelica Rojas Hernández would agree with that statement.
“There is a lack of recognition of the relative efficacy of demand reduction and harm reduction policies and the absence of an acknowledgement of the high costs that the prohibitionist and punitive approaches have generated,” she was quoted as saying by the Weed Blog. “The international community should continue to work toward the establishment of indicators that could help measure the impact of drug policies on people’s lives and their rights.”
And of course, changes to the treaties could also have an impact for businesses starting to establish themselves in the legal cannabis market. “There’s a really good chance that Canada, Israel, Jamaica, South America [could] be able to export to each other,” should a policy change come through, Brochstein stated. “This could really be an opportunity for countries that are on the verge, of or that have, national programs.”
Certainly, cannabis investors will want to keep an eye on the outcome of the UNGASS, and on any future developments with regards to the treaties mentioned above.
Don’t forget to follow us @INN_Resource for real-time news updates.
 
Securities Disclosure: I, Teresa Matich, hold no direct investment interest in any company mentioned in this article.

In the evolving rush of mergers and acquisitions (M&A) in the Canadian cannabis market, Canopy Growth (NASDAQ:CGC,TSX:WEED) announced it will acquire The Supreme Cannabis Company (TSX:FIRE,OTCQX:SPRWF) in a deal worth approximately C$435 million.

Meanwhile, a cannabis operator in the US confirmed this week that it will receive a financial boost from a partner to solidify its position in the burgeoning Pennsylvania state market.

Keep reading... Show less

The Board of Directors of Aphria Unanimously Recommends Shareholders Vote “For” the Arrangement

Aphria to Host Special Meeting of Shareholders on Wednesday, April 14, 2021 to Approve Proposed Aphria-Tilray Business Combination

Keep reading... Show less

Love Hemp Group PLC (AQSE: LIFE) (OTCQB: WRHLF), one of the UK’s leading CBD and Hemp product suppliers, announces that as part of the equity fundraise announced yesterday, Antony Calamita and Andrew Male, Directors of the Company, subscribed for 285,714 Ordinary Shares and 1,428,571 Ordinary Shares respectively. The subscriptions are at a price of 3.5 pence per ordinary share for a total of £60,000. Following these subscriptions, Antony Calamita is now interested in 54,385,714 Ordinary Shares, representing 8.61% of the Company’s share capital as increased by the fundraising, and Andrew Male is now interested in 6,138,196 Ordinary Shares, representing 0.97% of the Company’s issued share capital as increased by the fundraising

Further, the timetable for receipt of applications under the Broker Option, which was also announced yesterday, has been extended until 5:00 pm 9 April 2021 to capture additional interest which was unable to be completed yesterday.

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, would like to provide the following dial-in information for the Company’s upcoming Annual and Special Meeting (the “Meeting”) scheduled to be held at 11:00 a.m. Eastern Daylight Time on April 12, 2021. Shareholders and proxyholders may access the Meeting via teleconference by dialing 647-723-3984 or 1-866-365-4406 from Canada or the United States, then entering participation code “8487744” followed by the pound (“#”) sign.

In consideration of the COVID-19 pandemic and the recent restrictions imposed by the Ontario Provincial Government, shareholders and proxyholders will only be able to attend the Meeting via teleconference and will not be permitted to attend the Meeting in person at the address provided on the Notice of Annual and Special Meeting of Shareholders.

Keep reading... Show less

Gage Growth Corp. (“Gage” or the “Company”) (CSE:GAGE), a leading high-quality craft cannabis brand and operator in Michigan, announced today that it has signed an agreement with Blue River™ Extracts & Terpenes (“Blue River™”) to bring the brand’s award-winning solventless technology and other trademark branded products to the state’s medical patients and cannabis consumers. The Company will have exclusive rights to Blue River™’s premium product offerings in Michigan.

Keep reading... Show less